Accelerate Diagnostics (AXDX) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Accelerate Diagnostics has positioned itself for potential dilution risk after stockholders approved an increase in authorized common stock to 450,000,000 shares in May 2023. This move, aimed at providing flexibility for financing through various methods, could lead to significant dilution for current shareholders if the company issues more shares. The possible future issuance of substantial additional stock threatens to depress the market price of Accelerate Diagnostics’ shares, thereby posing a material risk to investors’ equity value.
The average AXDX stock price target is $2.00, implying 102.02% upside potential.
To learn more about Accelerate Diagnostics’ risk factors, click here.
